A consortium of investors led by Frontier Capital has funded the strategic merger of Inclinix with PMG Research, creating an organization designed to accelerate clinical trial enrollment from beginning to end. The company will be led by J. Tobin Geatz, President and CEO, and Jeffrey Reiniche, CFO.
"This novel business combination will allow sponsors and CROs to bundle the two most important services in a trial: world class sites and patient recruiting," noted Geatz. "We will have more than 120 Principal Investigators and 80 study coordinators, who together with Inclinix's 75+ global Clinical Enrollment Managers, provide our customers rapid enrollment locally and worldwide," he continued.
The company will operate in the short term as two divisions.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.